70 results about "Intestines mucosa" patented technology

The invention belongs to the technical field of biology, and particularly relates to a composition containing plant-derived exosomes as well as a preparation method and application of the composition. The invention provides a composition containing plant-derived exosomes. The composition is prepared from the following components in parts by mass: 1-60 parts of a plant-derived exosome preparation, 1-60 parts of chitosan oligosaccharide and 1-60 parts of probiotics. According to the composition provided by the invention, the plant-derived exosome, the probiotics and the chitosan oligosaccharide are compounded according to a specific proportion, so that the abundance of effective flora can be increased for a long time, the composition of intestinal flora can be improved, the structural balance of the intestinal flora can be regulated and maintained, the intestinal inflammation can be remarkably inhibited, the intestinal leakage can be improved, and the oxidative stress can be resisted; the repair of damaged intestinal mucosa and the elimination of inflammation are facilitated. The composition is safe and stable in raw materials, free of toxic and side effects and capable of being taken as daily diet.

The invention discloses application of breast milk-derived lactobacillus gasseri in reducing weight, reducing blood fat, preventing and treating type 2 diabetes mellitus, relieving intestinal leakage and inhibiting intestinal pathogens, and belongs to the technical field of microorganisms and the technical field of medicines. The invention provides a new application of lactobacillus gasseri in reducing weight, reducing blood fat, preventing and treating type 2 diabetes, relieving intestinal leakage and inhibiting intestinal pathogens. The traditional Chinese medicine composition can effectively prevent weight gain, body fat rate increase, low-density lipoprotein cholesterol and triglyceride increase of mice caused by high-fat diet, inhibit postprandial blood sugar and insulin resistance index increase, inhibit intestinal mucosa damage and growth of intestinal pathogenic bacteria, and effectively improve chronic diseases of mice with high-fat diet. Therefore, the lactobacillus gasseri FN136 has a huge application prospect in preparation of products for reducing weight, reducing blood fat, preventing and treating type 2 diabetes mellitus, relieving intestinal leakage and inhibiting intestinal pathogens.

The invention provides a preparation method and application of polygonatum cyrtonema acidic polysaccharide, and belongs to the technical field of polygonatum cyrtonema polysaccharide extraction. According to the invention, a separation and purification method combining anion exchange chromatography with gel chromatography is adopted, and finally the polygonatum cyrtonema acidic homogeneous polysaccharide (PCPA) with relatively high purity is obtained. An in-vivo pharmacodynamic experiment shows that the prepared PCPA can remarkably relieve intestinal mucosa injury and has relatively high intestinal immune regulation activity. The preparation method provided by the invention is stable in process, and the prepared polygonatum cyrtonema acidic polysaccharide is high in purity, is a homogeneous polysaccharide and has the effect of regulating intestinal immunity.

The invention discloses a phosphoric acid compound capable of resisting intestinal bacterial adhesion as well as a preparation method and application of the phosphoric acid compound, and belongs to the technical field of foods and medicines. The phosphoric acid compound is prepared from an amino-rich compound, a solution containing a phosphate compound with the mass concentration being 3% or above, a solution containing a zinc compound with the mass concentration being 3% or above, glucomannan, an alkaline solution and water. The phosphoric acid compound can effectively inhibit the adhesion of bacteria to intestinal mucosa, can control the probability of intestinal bacteria invasion, reduce the occurrence probability of intestinal leakage, control chronic inflammation in the body, can solve the intestinal health problem caused by the adhesion of intestinal bacteria, and plays an important role. In order to ensure the safety of the product and not introduce reagents and substances harmful to health, the used preparation process and production process are simple and easy to industrially amplify, harmful substances are prevented from being generated in the production process, the operation is easy, and large-scale production can be realized.

The invention relates to the technical field of medical biology, and provides a sheep-derived high-titer-ratio glycosaminoglycan mixture and a preparation method thereof.The preparation method comprises the following steps that S1, sheep intestinal mucosa crude heparin is dissolved, adsorbed, washed and eluted and then collected, and macromolecular sheep-derived glycosaminoglycan is obtained; s2, dissolving the macromolecular sheep-derived glycosaminoglycan, adding sodium nitrite for degradation, adding sodium borohydride for reduction, performing ultrafiltration, collecting a liquid medicine m1 at a filter-out end, and collecting a liquid medicine M1 at a reflux end; s3, sodium nitrite is added into the liquid medicine M1 for degradation, sodium borohydride is added for reduction, and liquid medicine m2 is obtained; s4, mixing the liquid medicine m1 and the liquid medicine m2, and performing ultrafiltration concentration, oxidation and precipitation to obtain the sheep-derived high-titer-ratio glycosaminoglycan mixture. Through the technical scheme, the preparation of the anticoagulant and antithrombotic glycosaminoglycan mixture with different weight-average molecular weight segments and titer ratios can be realized, and the problems of single source supply of low-molecular heparin and low applicability of the preparation process in the related technology are solved.

The invention belongs to the technical field of biomedical information analysis, and particularly relates to duodenum mucosa surface replacement and electrotransfection integrated equipment and a parameter feedback-based operation method. The invention firstly provides a duodenum mucosa surface replacement and electrotransfection integrated device. The device comprises an endoscope guide module, a radio frequency ablation module, an electrotransfection module and an intelligent terminal control module. The invention further provides a method for operating the DMR-EP integrated equipment based on organization parameter feedback. According to the method, individualized strategy generation and data-driven treatment path selection in DMR postoperative local gene therapy are proposed for the first time, and the safety, effectiveness and indication range of treatment are remarkably improved.

The present application relates to the technical field of pathological image classification, in particular to an intestinal mucosa tissue pathological image classification method and system based on artificial intelligence. The present application selects a histopathological region from a suspected pathological region, divides a sequence obtained by sequentially arranging the histopathological region into different subsequences, acquires pathological feature templates of the subsequences under each disease category, determines the disease category to which the histopathological region in the subsequence belongs according to the similarity between the texture distribution, blood vessel distribution characteristics of the histopathological region in the subsequence and the pathological feature templates, and acquires the feature templates of each subsequence under each disease category according to the pathological features of the histopathological region belonging to the same disease category and the pathological feature templates of the previous subsequence of each subsequence under each disease category. The present application realizes gradual and accurate matching of the pathological feature templates through dynamic and iterative optimization of the feature templates with the subsequences, and increases the accuracy of pathological feature matching of the intestinal mucosa pathological position.

The invention discloses a medicine for relieving side effects of gastrointestinal tracts caused by nintedanib, a medicine for preventing or treating pulmonary fibrosis and application of stachyose, and belongs to the technical field of medicines. The medicine taking the stachyose as the active ingredient can effectively relieve gastrointestinal tract side effects caused by the nintedanib, for example, intestinal mucosa lesions caused by the nintedanib can be obviously relieved, for example, intestinal mucosa tissue structure abnormity, intestinal cell proliferation activity reduction, intestinal cell apoptosis increase, intestinal tissue inflammatory factor gene expression level up-regulation and the like.

The present invention belongs to the field of biomedicine technology, and specifically discloses the application of Lactobacillus delbrueckii surface protein in the preparation of products that improve intestinal inflammation. The new use of Lactobacillus delbrueckii surface protein provided by the present invention, including the application in the preparation of a medicine for preventing and / or treating ulcerative colitis. Cell and animal experimental results show that Lactobacillus delbrueckii surface protein can alleviate DSS-induced ulcerative colitis in mice, improve weight loss, shortened colon length and colon mucosal damage, reduce proinflammatory cytokine (such as IL-1β, IL-6) content in the colon, increase anti-inflammatory cytokine (such as IL-10) content, reduce proinflammatory macrophage ratio in spleen and colon, inhibit macrophage proinflammatory phenotype, can be used for the preparation of products that improve intestinal inflammation, and has good application prospects and potential clinical treatment value.

The invention relates to medicinal and edible meal replacement powder for regulating intestines and stomach and a preparation method thereof. The fried coix seed powder and the Chinese yam powder are used as main grain base materials and have the effects of strengthening the spleen, nourishing the stomach and repairing intestinal mucosa, the banana powder and the apple pectin rich fibers are matched and can moisten the intestines and regulate the intestines and the stomach, the poria cocos powder can strengthen the spleen, soothe the nerves and inhibit harmful bacteria, and the endothelium corneum gigeriae galli powder and the fried maltol have the effects of promoting digestion, relieving stasis, promoting the circulation of qi and relieving flatulence. The sweet osmanthus powder and coconut powder are supplemented, so that the fragrance and taste of the meal replacement powder can be improved, essence components are not needed, and the components are more natural and harmless. In the preparation process, coix seeds and malt are stir-fried to stimulate fragrance, low-temperature drying of Chinese yam retains mucus protein, after irradiation sterilization treatment, effective components are effectively retained, component loss is avoided, and the gastrointestinal regulation effect of the meal replacement powder is achieved through combination of traditional processing and a modern food technology.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ackermania muciniphila and recombinant trichina serine protease carried by a derivative of the ackermania muciniphila to preparation of a medicine for treating intestinal inflammation symptoms. According to the present invention, the ackermann muciniphila and the ackermann muciniphila derivative carrying recombinant trichina serine are firstly disclosed, such that the physical barrier of the intestinal mucosa is repaired through the synergistic effect, the expression of TNF-alpha, IL-6, IL-1beta and other proinflammatory factors is specifically regulated and inhibited, the intestinal flora structure is remodeled, and the intestinal inflammation state is significantly improved; experimental results show that the Ackerman muciniphila and the derivative thereof carrying the recombinant trichina serine protease can significantly relieve weight loss of mice with intestinal inflammation induced by DSS, reduce DAI score, and reverse the phenomena of shortened colon and abnormal swelling of spleen. According to the invention, the probiotics and the parasite-derived protein are combined, so that the method has the advantages of high efficiency, safety and easiness in large-scale production, and a new biological preparation strategy is provided for accurate treatment of IBD.

The invention discloses a method for extracting genome DNA (deoxyribonucleic acid) from intestinal mucosa tissue and application, the extraction method comprises the following steps: mixing the intestinal mucosa tissue with lysis buffer, physically homogenizing with a homogenizing rod, precipitating with absolute ethyl alcohol, purifying and collecting DNA, and the tissue lysis buffer contains Tris-HCl, Urea, CHAPS, SDS (sodium dodecyl sulfate) and PMSF. According to the extraction method, DNA can be rapidly and effectively extracted from intestinal mucosa tissues, a foundation is laid for subsequent intestinal mucosa 16S rRNA strain identification, and meanwhile a reference basis is provided for DNA extraction of other tissue samples.

The present invention discloses the application of a Lactobacillus gasseri strain derived from breast milk in weight loss, blood lipid reduction, prevention and treatment of type 2 diabetes, alleviation of intestinal leakage and inhibition of intestinal pathogenic bacteria, belonging to the fields of microbial technology and pharmaceutical technology. The present invention provides a new use of Lactobacillus gasseri in weight loss, blood lipid reduction, prevention and treatment of type 2 diabetes, alleviation of intestinal leakage and inhibition of intestinal pathogenic bacteria, which can effectively reduce the prevention of weight gain, increase in body fat percentage, elevation of low-density lipoprotein cholesterol and triglycerides, inhibition of postprandial blood glucose and insulin resistance index elevation, inhibition of intestinal mucosal damage and growth of intestinal pathogenic bacteria caused by high-fat diet, and effectively improve the occurrence of chronic diseases in high-fat diet-fed mice. Therefore, Lactobacillus gasseri FN136 has great application prospects in the preparation of products for weight loss, blood lipid reduction, prevention and treatment of type 2 diabetes, alleviation of intestinal leakage and inhibition of intestinal pathogenic bacteria.

The invention relates to the technical field of pathological image classification, in particular to an intestinal mucosa tissue pathological image classification method and system based on artificial intelligence. The method comprises the following steps: selecting histopathological regions from suspected pathological regions, and dividing a sequence obtained by sequentially arranging the histopathological regions into different subsequences; acquiring a pathological feature template of the sub-sequence under each disease category, and determining the disease category to which the tissue pathological area in the sub-sequence belongs according to the similarity between the texture distribution and blood vessel distribution features of the tissue pathological area in the sub-sequence and the pathological feature template; and according to the pathological feature template of the previous sub-sequence of each sub-sequence under each disease category and the pathological features of the histopathological region belonging to the same disease category, obtaining the feature template of each sub-sequence in each disease category. According to the method, through dynamic iterative optimization of the feature templates along with the subsequences, progressive accurate matching of the pathological feature templates is realized, and the accuracy of pathological feature matching of the pathological positions of the intestinal mucosa is increased.

The application discloses a sophora japonica composition for refractory enteritis and a preparation method and application thereof. The sophora japonica composition for refractory enteritis comprises the following components: sophora japonica, dried orange peel, panax notoginseng, momordica grosvenori and lycoris radiata, and the sophora japonica composition for refractory enteritis is obtained by fermenting plant lactobacillus. The sophora japonica composition for refractory enteritis of the application can obviously increase the amount of duhrlactobacillus, lactobacillus and bifidobacterium and reduce the amount of clostridium in the process of treating inflammatory enteritis; can effectively inhibit the inflammation of colitis, and the mRNA level of inflammatory cytokines TNF-alpha, IL-22, IL-1beta and IL-6 is obviously reduced. The sophora japonica composition can obviously inhibit intestinal inflammation, promote the metabolism of intestinal short-chain fatty acids, increase the thickness of intestinal mucosa, and has obvious curative effects on intestinal microecological homeostasis of inflammatory bowel disease, intestinal inflammation and protection of intestinal mucosa.

The invention discloses an agaro-oligosaccharide oral solution with a constipation relieving function, and belongs to the technical field of food biology. The invention provides a preparation method of agarotriose. Main components which mainly exert anti-inflammatory activity are analyzed through clinical evaluation. According to the invention, agarotriose is extracted by adopting an enzymolysis method to treat LOP-induced constipation mice, and the influence of main components on model mice is investigated from the aspects of excrement water content, small intestine propulsion rate, first-grain black excrement discharge time, colon pathological structure and the like. Experimental results show that compared with an LOP group, the agarotriose high-dose group can significantly improve constipation symptoms, relieve inflammatory response and promote colonic mucosa repair, so that agarotriose can be used as a good functional food for relieving constipation.

The invention provides a donkey milk exosome preparation, a preparation method and application, and belongs to the technical field of life sciences, the donkey milk exosome preparation comprises a donkey milk exosome and a complex microbial inoculant; wherein the complex microbial inoculant is prepared from clostridium butyricum, bacillus subtilis and enterococcus faecium. The scheme that the donkey milk exosome and the complex microbial inoculant are compounded for use is created for the first time, and the donkey milk exosome and the complex microbial inoculant can achieve synergistic interaction, so that inflammatory factors can be effectively reduced, the number of goblet cells is increased, and the intestinal mucosa is repaired; meanwhile, by utilizing the natural anti-inflammatory property of the donkey milk exosome and the micro-ecological regulation of the complex microbial inoculant, the side effects of chemical drugs are avoided, and an integrated scheme of'intestinal barrier repair-immune regulation 'is provided.

The utility model discloses a heparin sodium preparation salt hydrolysis reaction device, which relates to the heparin sodium preparation salt hydrolysis reaction field, and comprises a bottom plate, the upper end of the bottom plate is fixedly connected with a support rod, the upper end of the support rod is fixedly connected with a reaction barrel, and the upper end of the reaction barrel is fixedly connected with a crushing barrel; the upper end of the crushing barrel is fixedly connected with a driving assembly, the upper end of the crushing barrel is fixedly connected with a first feeding opening, the interior of the reaction barrel is fixedly connected with a partition plate, a stirring assembly is arranged at the position, located in the reaction barrel, of the lower end of the crushing barrel, and a crushing assembly is arranged in the crushing barrel. By the adoption of the structure, the driving assembly is started to enable the first driving gear to drive the crushing gear to rotate, so that the crushing gear rotates to enable the crushing rod to rotate and then drive the crushing piece to rotate, and the intestinal mucosa can be crushed under the action of the crushing piece.

The invention provides an exosome oral soluble film with a multi-targeting function, which is prepared from the following components in parts by weight: 10 to 20 parts of active substances, 20 to 60 parts of carrier materials for wrapping exosomes or drug-loaded exosomes, 50 to 100 parts of film-forming agents, 20 to 40 parts of disintegrating agents, 10 to 25 parts of plasticizers, 1 to 5 parts of flavoring agents and 1 to 10 parts of antioxidants, wherein the active substance is an exosome or a drug-loaded exosome, and the carrier material is a polylactic acid-glycolic acid copolymer-sulfydryl group, polyethylene glycol and polyethylene glycol diacrylate. According to the scheme, the carrier material entrapped with the exosome has a dual targeting effect, so that the exosome or the exosome loaded with the medicine can accurately reach the ulceration position of the colonic mucosa, and accurate treatment is achieved; and the exosome is administrated in an oral dissolution manner, so that a patient can take the exosome with high compliance.

The invention belongs to the technical field of medicines, and particularly relates to a golden flower and fruit extract for treating ulcerative colitis. According to the traditional Chinese medicine composition, natural medicine components are extracted from golden flower and fruit, the components can enhance the shielding guarantee effect of colonic mucosa, reduce inflammation gene expression, prevent colon shortening and improve the curative effect of ulcerative colitis, and the traditional Chinese medicine composition has a good application prospect.

The invention provides an application of a combined composition of antibiotics and bacteria carrying DL-endopeptidase in preparation of a medicine for preventing intestinal development delay of premature infants, the combined composition comprises a component A and a component B which are prepared according to a specific mass ratio, the component A is selected from broad-spectrum antibiotics in an intensive care unit of newborns, and the component B is selected from bacteria carrying DL-endopeptidase and bacteria carrying DL-endopeptidase and bacteria carrying DL-endopeptidase and bacteria carrying DL-endopeptidase. And the component B is a strain which can secrete DL-endopeptidase and has endogenous drug resistance to the component A. According to the application, synergism of'clearing 'and'driving' is realized, the traditional clinical thinking of'first sterilization and then remediation 'is broken, pathogenic microorganisms (such as klebsiella and staphylococcus aureus) in a premature infant body are cleared through antibiotics, and meanwhile, bacterial components in the components are synchronously utilized to down-regulate protein expression of the intestinal mucosa intracellular cylindricity disease, so that the premature infant is prevented from suffering from the intestinal mucosa intracellular cylindricity disease, and the premature infant is prevented from suffering from the intestinal mucosa intracellular cylindricity disease. The synthesis of tight junction protein is actively realized.

The use of a probiotic, in particular an Enterococcus faecium strain named SF68, for the treatment of disorders characterized by alterations of the intestinal mucosa, particularly inflammations associated with altered intestinal permeability is described.

The present invention provides an anionic polymer grafted covalent organic framework material and a preparation method and application thereof. The covalent organic framework material COF-V is synthesized by polymerizing 1,3,5-tri(4-aminophenyl)benzene and 2,5-divinyl-1,4-phthalaldehyde, and polymer hair is grafted on the surface of COF-V using 2-acrylamido-2-methyl-1-propanesulfonic acid as a monomer to obtain a novel covalent organic framework molecular brush COF- g ‑PAMPS. COF‑ g On the one hand, ‑PAMPS has the high chemical stability of COF‑V materials and can resist gastric acid, making it suitable as a drug delivery platform for oral drugs; on the other hand, it can carry a negative charge in aqueous solution and has the characteristics of mucosal adhesion and receptor interaction when used as a drug delivery platform, which is conducive to adhering to the positively charged inflamed colon mucosal surface and targeted release of drugs.

This invention belongs to the field of bacterial agent preparation and biomedical technology, specifically relating to a strain of *Lactobacillus reuteri*, a bacterial agent, and its application in treating ulcerative colitis. This invention isolated a strain of *Lactobacillus reuteri*, named PFL-2501, and preserved it biologically. The *Lactobacillus reuteri* PFL-2501 exhibits strong gastrointestinal tolerance and high safety, with no hemolytic properties. It can inhibit harmful pathogenic bacteria in the intestine, regulate immune balance, reduce the content of pro-inflammatory factors in colonic tissue, decrease peroxidase activity, increase the level of anti-inflammatory factors, and improve the expression of intestinal tight junction proteins. The results of the examples show that *Lactobacillus reuteri* PFL-2501 and its bacterial agent can reduce weight loss in ulcerative colitis model mice, reduce the disease activity index, prolong colon length, protect the integrity of the colonic mucosa, and reduce inflammatory damage, thereby achieving a significant effect in alleviating ulcerative colitis.

The invention discloses a preparation method of a seawater fish fermented feed containing lactobacillus pentosus, and belongs to the field of aquaculture feed preparation, and the preparation method comprises the following steps: screening out a lactobacillus pentosus strain from intestinal tracts of healthy seawater fish (trachinotus ovatus); preparing a lactobacillus pentosus fermentation broth, a bacillus subtilis fermentation broth, a bacillus licheniformis fermentation broth and a wine brewing active dry yeast fermentation broth; mixing the lactobacillus pentosus fermentation broth, the bacillus subtilis fermentation broth, the bacillus licheniformis fermentation broth and the wine brewing active dry yeast fermentation broth according to a volume ratio of 2: 1: 1: 2 to obtain a fermentation broth; mixing the zymophyte liquid with a marine fish puffed compound feed and a compound enzyme preparation; according to the present invention, the morbidity of enteritis of the marine fish can be significantly reduced, the marine fish can well digest food, the damaged intestinal mucosa can be effectively repaired, and the normal digestion and absorption function of the intestinal tract can be promoted. In addition, the feed can also improve the toughness of intestinal tracts and thicken intestinal walls, so that the normal physiological function of the intestinal tracts is enhanced.

The application provides a preparation method and application of a polygonatum cyrtonema acid polysaccharide, and belongs to the technical field of polygonatum cyrtonema polysaccharide extraction. The application adopts a separation and purification method of anion exchange chromatography combined with gel chromatography, and finally obtains a polygonatum cyrtonema acid uniform polysaccharide (PCPA) with high purity. In-vivo pharmacodynamic experiments show that the prepared PCPA can significantly relieve intestinal mucosa injury and has high intestinal immune regulation activity. The preparation method provided by the application is stable in process, the prepared polygonatum cyrtonema acid polysaccharide is high in purity, is a uniform polysaccharide, and has an intestinal immune regulation effect.

The application belongs to the technical field of heparin extraction, and particularly relates to a method for determining the abundance of high anti-IIa activity heparin of pig small intestinal mucosa. The method comprises the following steps: (1) crushing fresh pig small intestinal mucosa; (2) using a PowerSoil kit to lyse the mucosa cells crushed in step (1), and performing water bath at 50-65 DEG C for 10-20 min, and then adding an elution buffer to elute the DNA; (3) using PCR to amplify the eluted DNA solution; (4) using a Nextera XT DNA library preparation kit to construct a library, and then using an Illumina NovaSeq 6000 sequencer to perform high-throughput sequencing; (5) using a DADA2 process to denoise and remove chimeric sequences, and using a 97% similarity threshold to cluster to generate OTU, and using a Greengenes database to annotate; (6) then using an LEfSe algorithm to screen differential flora, and using a random forest model to predict heparin activity.

The present invention belongs to the field of biomedical information analysis technology, and specifically relates to an integrated device for duodenal mucosal surface replacement and electrotransfection and a method for operation based on parameter feedback. The present invention first provides an integrated device for duodenal mucosal surface replacement and electrotransfection, which includes an endoscopic guidance module, a radiofrequency ablation module, an electrotransfection module, and an intelligent terminal control module. The present invention also provides a method for operating a DMR-EP integrated device based on tissue parameter feedback. The present invention proposes for the first time the realization of individualized strategy generation and data-driven treatment path selection in local gene therapy after DMR surgery, which significantly improves the safety, effectiveness, and breadth of indications of the treatment.

The invention provides an anionic polymer grafted covalent organic framework material as well as a preparation method and application thereof, and the preparation method comprises the following steps: polymerizing 1, 3, 5-tri (4-aminophenyl) benzene and 2, 5-divinyl-1, 4-phthalaldehyde to synthesize a covalent organic framework material COF-V; and further grafting polymer hair on the surface of the COF-V by taking 2-acrylamido-2-methyl-1-propanesulfonic acid as a monomer, so as to obtain the novel covalent organic framework molecular brush COF-g-PAMPS. On one hand, the COF-g-PAMPS has high chemical stability of a COF-V material, can resist gastric acid and is suitable for being used as a drug loading platform of oral drugs; on the other hand, negative charges can be carried in an aqueous solution, and when serving as a medicine carrying platform, the hydrogel has the characteristics of mucosa adhesion, receptor interaction and the like, and is beneficial to being adhered to the surface of inflamed colonic mucosa with positive charges and releasing medicines in a targeted manner.

The invention relates to the technical field of biology, in particular to a polygonum viviparum general flavone extraction method and application, in the extraction method, multiple factors are screened, the method with the highest extraction efficiency is obtained, and the method has the advantages of being high in extraction rate, low in cost, easy and convenient to operate, safe, environmentally friendly and the like, and is high in comprehensive cost performance and suitable for large-scale production; the polygonum viviparum general flavone can restore the reduction of the thickness of an intestinal mucosa layer and enhance the intestinal barrier function by adjusting the level of inflammatory cytokines so as to protect the intestinal tract of an LPS-induced enteritis mouse; the effect of the DSS on the abundance of the microflora is reversed, the effects of regulating the intestinal flora and repairing the intestinal epithelial barrier injury are achieved, and the potential effects of treating the intestinal epithelial barrier injury, the intestinal flora disorder and the uric acid level abnormity in digestive tract diseases are achieved; the compound is expected to be further developed into a pure natural plant flavonoid medicinal preparation for treating digestive tract diseases.